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Abstract
Background: Much research has been devoted to the development of new breast cancer diagnostic measures, including
those involving high-resolution magic angle spinning (HR-MAS) magnetic resonance (MR) spectroscopic techniques.
Previous HR-MAS MR results have been obtained from post-surgery samples, which limits their direct clinical applicability.
Methodology/Principal Findings: In the present study, we performed HR-MAS MR spectroscopic studies on 31 breast tissue
samples (13 cancer and 18 non-cancer) obtained by percutaneous core needle biopsy. We showed that cancer and non-
cancer samples can be discriminated very well with Orthogonal Projections to Latent Structure-Discriminant Analysis (OPLS-
DA) multivariate model on the MR spectra. A subsequent blind test showed 69% sensitivity and 94% specificity in the
prediction of the cancer status. A spectral analysis showed that in cancer cells, taurine- and choline-containing compounds
are elevated. Our approach, additionally, could predict the progesterone receptor statuses of the cancer patients.
Conclusions/Significance: HR-MAS MR metabolomics on intact breast tissues obtained by core needle biopsy may have a
potential to be used as a complement to the current diagnostic and prognostic measures for breast cancers.
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Introduction
Magnetic resonance (MR) spectroscopic techniques has been a
primary method employed in investigations of metabolite changes
in biofluids such as urine, blood, and bile [1,2,3]. Recent
technological advances have enabled detection of metabolites also
in intact tissues, using magic angle spinning (MAS) methods [4].
MAS narrows the line widths of metabolite signals by eliminating
dipolar relaxation in the semi-solid tissues through rapid sample
spinning (typically.=2000 Hz) at a magic angle (54.7 degrees)
against the magnetic field. The resulting spectra show features
with high resolution (HR) that are typically seen in solution MR
data [4]. Such HR-MAS MR spectroscopy has been applied in
metabolomics studies on breast, prostate, liver, colon, and lung
tissues [5,6,7,8,9,10]. In the case of breast cancer tissues, several
studies employing HR-MAS MR have addressed issues including
metabolite identification, diagnostic usefulness, and prognostic
marker correlation [11,12,13,14]. However, these studies were
conducted retrospectively with surgically obtained tissues; their
results, therefore could not be directly applicable to surgical
decision making or to cancer patients that do not need axillary
dissection. Samples alternatively obtained by minimally invasive
fine needle aspiration biopsy (FNAB) or core needle biopsy before
surgery would, in fact, be applicable. A standard high-resolution
MR (non-HR-MAS) spectroscopic study with FNAB has been
conducted, but it, too, used intraoperative samples [15].
Moreover, this method would be ineffective with breast tissue
samples obtained by core needle biopsy, due to the high lipid
contents of those tissues.
The data obtained via MR spectroscopic techniques are
inherently complex, and contain information on many metabo-
lites; such data, accordingly, have been analyzed by multivariate
analysis. Variables are reduced in number, and marker signals are
identified by the weights of the original variables in the reduced
variables that contribute to the differentiation of the classes of
interest. Principal component analysis (PCA), partial least square-
discriminate analysis (PLS-DA), and neural networks are among
the frequently-used methods for breast cancer metabolomics
studies [12,16]. Recently, Orthogonal Projections to Latent
Structure-Discriminant Analysis (OPLS-DA) was proposed as an
PLoS ONE | www.plosone.org 1 October 2011 | Volume 6 | Issue 10 | e25563effective tool for metabolomic analysis [17,18]. The main merit of
OPLS-DA is its separation of the class-orthogonal variations that
can obscure class differentiation. It is similar to the combination of
orthogonal signal correction and PLS-DA, but, advantageously,
can be completed in a single analysis. Its utility in fact has been
shown in many metabolomics studies in which intra-group
variation is very large [1,19,20].
We prospectively conducted HR-MAS MR spectroscopic
studies on breast tissue samples obtained by percutaneous core
needle biopsy. We employed CPMG pulse sequence which can
selectively suppress signals with short relaxation times, most
notably, lipid signals abundant in core needle biopsy samples. An
OPLS-DA analysis yielded information on elevated metabolites in
the cancer samples as well as quantitative measures on the
performance of our approach in classification and blind sample
prediction. On the basis of the results, we believe that minimally
invasive core needle biopsy combined with the HR-MAS MR
metabolomics approach may complement the currently existing
breast cancer diagnostic and assessment measures.
Results
HR-MAS MR spectra of core needle biopsy samples
The 31 breast tissue samples (13 cancer, 9 benign and 9 normal)
obtained by core needle biopsy were examined, and the
representative MR spectra of cancer and non-cancer samples
are shown in Fig. 1. As has been the case with spectra previously
reported for samples obtained through surgery, our MR spectra
featured large peaks at 0.91 and 1.31 ppm due to the aliphatic
fatty acid sidechains of lipids. These peaks were by far the most
intense, even with the CPMG T2 filter and regardless of the
cancer status, indicating that it is not easy to avoid inclusion of
adipose tissues in core biopsy samples. The intensity variations of
those signals were so large as to dwarf those of any others.
Therefore, we excluded them from the subsequent analysis. Still,
there were readily observable and reasonably resolved signals in
the 2.2,4.2 ppm region. In addition, the S/N ratios were
adequate for identification of a number of metabolites that have
been reported in surgically obtained samples (Fig. 1).
Figure 1. HR-MAS MR spectra of breast tissue samples obtained by 14-gauge core needle biopsy. Representative 500 MHz HR-MAS MR
spectra of breast samples from a cancer patient (upper) and a non-cancer patient (lower). The spectra were taken for an average of 12.2 mg of core
needle biopsy samples in D2O and 0.01% TSP with CPMG pulse sequence and 2 KHz spinning. Individual choline species were identified according to
previous reports [13,36] and comparison with an authentic choline sample.
doi:10.1371/journal.pone.0025563.g001
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As it was difficult to isolate differences between the patient
groups by simple visual inspection due to the large intra-group
variation, we performed a multivariate statistical analysis for a
more holistic view of the data. We used the 0.99,5.59 ppm
region, but excluded water and aliphatic fatty acid sidechains
signals, as stated above. Initially, we wanted to see if the approach
could discriminate among the three groups (cancer, benign tumor,
and normal), but found that it was not possible to distinguish
differences within the non-cancerous samples (benign tumor vs.
normal; data not shown). Therefore, we tried to build a model that
can address the difference between cancer and non-cancer groups
using the OPLS-DA approach, by which structured noise can be
dealt with efficiently [1,18,21]. The resultant OPLS-DA model,
for all of the 31 samples, separated the two major groups, cancer
(n=13) and non-cancer (n=18), without overlap using one
predictive and two orthogonal components (Fig. 2). Overall,
though each sample within a group showed considerable variation,
our model could discriminate them very effectively.
Although a perfect separation was achieved (see the Fig. 2: score
plot), it was yet possible that the distinction was due to model over-
fitting. Therefore, we performed a predictive test by leaving out
one patient sample at a time and constructing the OPLS-DA
prediction model with the rest of the data. The cancer or non-
cancer status of the left-out sample was then predicted based on
the new model. This step amounts, then, to a blind test for an
unknown sample, and as such can serve as a cross-validation for
the distinction model. The prediction approach was taken with the
same number of predictive and orthogonal components as in the
original OPLS-DA model. The class membership of the left-out
sample was predicted using an a priori cut-off value of 0.5. The
prediction results showed that the model correctly predicted 26
samples out of the total 31 (Fig. 3). Among the incorrectly
predicted samples were four cancer samples predicted as non-
cancer samples, and one non-cancer sample predicted as a cancer
sample. Thus, the sensitivity, specificity, and accuracy were 69%
(9/13), 94% (17/18), and 84% (26/31), respectively, in the
prediction of the cancer status.
Analysis of group-relevant signals
After the establishment of the model, we tried to identify the
variables responsible for the differentiation of the cancer and non-
cancer groups. We built an S-plot that shows the modeled
correlation (p(corr)p) and covariation (pp) in a single figure, enabling
easy selection of significant markers among noisy signals. The
p(corr)p values of the signals suggest that multiple signals account for
group differentiation (Fig. 4) [1,2]. Still, we could pick up 3.43 and
2.77 ppm signals as the most reliable contributors for the cancer
and non-cancer groups, respectively, as they had large values for
both correlation and covariation. Based on the above signal
assignments, the signals were identified as coming from taurine
(3.43 and 3.26 ppm) and aspartate (2.77 ppm). The assignment of
aspartate was tentative, though, as its signal was broad and possibly
overlapped with those from other metabolites. The signals from
choline-containing compounds (3.22,3.24 ppm), particularly
phosphocholine centered at 3.230 ppm, were also correlated with
the cancer group. To test the statistical validity of the signals found
by this multivariate analysis, we carried out a Mann-Whitney U-test
(Fig. 5) [22]. In addition, we obtained the average spectra of each
group after normalization and alignment (Fig. 5). Both of these
analyses showed that taurine and aspartate had a biased distribution
in the cancer and non-cancer groups, respectively.
Correlation with prognostic markers
Based on the cancer/non-cancer correlation with the MR
spectral data, we tested if PR status, an important prognostic
marker, can also be correlated. We divided the cancer patient
group into two according to the PR status (positive or negative),
and obtained an OPLS-DA separation model of the MR data of
each group (Fig. 6A). Although we observed cross-over of some
samples along the pp line of the model, we could see general
clustering of the samples into their respective regions. We also
tested the predictability of the model on blind samples using the
same method used for cancer/non-cancer status. Out of the total
of 13 cancer samples, 10 were predicted correctly and 3 were mis-
predicted, with 1 PR-positive and 2 PR-negative samples among
the latter. Other important prognostic markers, ER status and
HER-2/neu, could not be evaluated, due to the small number of
patients with ER negative (n=2) and HER-2/neu negative (n=1)
in our cancer patient group (See Table 1).
We also evaluated the correlation of MR spectral data with the
axillary lymph node metastasis status. Inclusion of all of the cancer
patients (metastasis=4, non-metastasis=9) did not yield a reliable
discrimination model. Exclusion of two possible outliers (both from
the non-metastasis group) based on a PCA and subsequent OPLS-
DA modeling resulted in a reasonable distinction between the two
groups (Fig. 6B). Three of the four samples in the axillary lymph
node metastatic group could be separated from seven samples in
the non-metastatic group.
Discussion
We evaluated the relevance of HR-MAS MR metabolomics to
core needle biopsy samples in breast cancer diagnostics. Although
there have been studies using similar spectroscopic techniques on
surgically obtained breast cancer samples, there have been none,
to our knowledge, that have utilized intact breast tissue obtained
by 14-gauge core needle biopsy. As percutaneous image-guided
biopsy using an 8–14 gauge needle is a standard procedure for
inspecting suspicious breast lesions in most hospitals, the results
can be directly translated into real clinical situation. Another
important advantage of our approach is that HR-MAS MR
spectroscopy is non-destructive, enabling re-use of samples for
Figure 2. Multivariate discrimination model for cancer and
non-cancer samples. Orthogonal Projections to Latent Structure-
Discriminant Analysis (OPLS-DA) score plot for cancer and non-cancer
samples. The model was obtained using one predictive and two
orthogonal components. Filled box and solid line: cancer samples; open
triangle and dotted line: non-caner samples.
doi:10.1371/journal.pone.0025563.g002
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degradation of the tissue samples after HR-MAS MR spectroscopy
and successfully performed H&E staining and immunohistochem-
istry analysis. One possible caveat regarding the core biopsy
approach is the small amount of the obtained sample and
uncertainties associated with the actual sampling positions for
small tumors. Still, it seems that the metabolomics approach might
be more suited to analyzing core-biopsy samples than other-omics
approaches. This is due to the fact that the small molecules
analyzed by MR-based metabolomics are more diffusible than
proteins or DNA molecules, and, therefore, can reflect the status of
neighboring tissues better than much larger macromolecules.
Again, the non-destructive nature of the technique is in contrast
with proteomics and genomics, which entail sample destruction.
The current study used normal and benign tissue samples for
comparison with cancer samples, unlike previous studies, which
used non-involved tissues from cancer patients [11,15,16,23]. In
addition, these earlier studies included relatively advanced-cancer
patients undergoing surgery, which fact might have facilitated the
tissue distinction. Therefore, our patient group might be more
variable even though the sample size is much smaller than some of
the previous ones.
Mountford et al. reported the diagnostic utility of ex vivo HR-
MR spectroscopy combined with linear-discriminant analysis
Figure 3. Prediction result for cancer status based on OPLS-DA model. One patient sample was left out at a time, and a new OPLS-DA
prediction model was constructed withthe rest of the data. The class membership of the left-outsamples was predictedusing an a prioricutoff value of 0.5
(dashed line). Filled box: cancer samples, filled triangle: non-cancer samples. The Y values of the filled symbols are from the analysis using the entire dataset.
In the case of mis-classified samples, the predicted Y values are also shown as open boxes (cancer samples) and open triangles (non-cancer samples).
doi:10.1371/journal.pone.0025563.g003
Figure 4. Signals contributing to differentiation. Signals contrib-
uting to the differentiation of cancer and non-cancer samples are plotted
based on their p(corr)p and pp values. These values represent modeled
correlation and modeled covariation, respectively. The most relevant
chemical shift values are shown next to the symbols representing the
signals.
doi:10.1371/journal.pone.0025563.g004
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tried the same approach for core needle biopsy samples, but were
unsuccessful due to the high fat content masking diagnostic signals
[15]. The successful discrimination of cancer status with core
needle biopsy samples in our present study was owed to several
methodological differences. First, we used HR-MAS, which can
significantly narrow the line width of signals from semi-solid tissue
samples. This line-narrowing is directly translated into increased
signal intensities. Second, we also employed CPMG pulse
sequence, which can selectively suppress signals with short
relaxation times, most notably, lipid signals. This increases the
relative contributions of other regions that carry diagnostic
information. Third, despite the use of the above spectroscopic
techniques, saturated fatty acid signals were the most intense
peaks. Therefore, we removed those regions from the spectra and
normalized the data with the total integral of the remaining
regions. This step proved to be particularly important, as a variety
of other normalizations failed to produce acceptable results. In
addition to the above measures to obtain or process the spectral
data, the use of OPLS-DA multivariate analysis [17,18] also
contributed to our results. OPLS-DA is different from PLS-DA in
that it rotates the score matrix so that the class-orthogonal
variation can be separated from the class-predictive one.
Therefore, it can provide easier interpretation of the factors
contributing to class difference in the presence of large intra-group
variation, such as that seen in the current case. HR-MAS MR
spectroscopy with CPMG pulse sequence has been applied to
tissue samples obtained during surgical procedures [11,12,14,23].
Figure 5. Average spectra and Mann-Whitney U test for marker signals. The levels of the makers identified by the multivariate analysis were
assessed by average spectral plot and Mann-Whitney U-test. A and B: Normalized and averaged intensities of the indicated marker signals from the
cancer and non-cancer samples. C and D: Box plots of the Mann-Whitney U test results with the resulting p values. In all of the plots, red represents
the non-cancer samples and blue the cancer samples.
doi:10.1371/journal.pone.0025563.g005
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cases [14], whereas, in core needle biopsy, their contents cannot be
controlled, and the resulting samples may be difficult to analyze
with more conventional approaches. OPLS-DA has been also used
successfully to analyze other demanding metabolomic cases
[1,20,24], including the one concerning data obtained from
genetically homogenous animals [25].
In addition to the above stated merits, OPLS-DA provided
easily interpretable data (S-plot, see Fig. 4) concerning metabolites
relevant to discrimination of cancer and non-cancer groups. Our
data showed that taurine and choline-containing compounds,
especially phosphocholine, were elevated in the cancer samples
compared with the non-cancer ones. Choline-containing com-
pounds have been found to be elevated in breast cancer
[26,27,28], as well as in other malignancies [29]. In addition,
phosphocholine level was higher in breast cancers or cancer cell
lines than normal counterparts [30,31,32]. Taurine levels have
also been known to be higher in prostate [33] and breast cancers
[34]. This consistency supports the relevance of our approach
using minimally invasive HR-MAS MR spectroscopy with core
needle biopsy in metabolite analysis of cancer tissues. There have
been several studies on the diagnostic performance of MR
spectroscopic techniques with biopsy-obtained breast cancer
samples. In one such report, HR-MR spectroscopic data on
intraoperative FNAB samples analyzed by multivariate analysis
showed 94% sensitivity and 98% specificity in discriminating
cancer and non-cancer tissues [15]. Another study using HR-MAS
MR spectroscopy on surgically obtained tissue samples reported
82% sensitivity and 100% specificity based on the intensities of
choline-containing compounds [13]. It should be noted that the
values of the former study were obtained with only a training set,
and those of the latter were from an intensity comparison of
choline that is not applicable to multivariate blind tests. If we apply
the same criterion, that is, diagnostic performance on a training set
without a blind test, to the OPLS-DA classification model, we
obtain 100% for both sensitivity and specificity based on the
predictive component. However, these approaches tend to yield
over-optimistic values, and more relevant estimation should be
obtained with blind tests using samples that were not used to build
the classification model [12]. It is notable that blind sample
prediction was done to evaluate the performance of prognostic
markers from surgical samples in later studies [12,16]. A blind test
on our data set, excluding one sample at a time until all of them
had been left out showed 69% sensitivity, 94% specificity and 84%
accuracy. Another intriguing feature of our results is the correct
blind-test prediction of ductal carcinoma in situ, a very early stage
Figure 6. Discrimination based on prognostic markers: PR and lymph node metastases. OPLS-DA score plots based on the statuses of
progesterone receptor (A) and lymph node metastasis (B). All of the models were obtained using one predictive and two orthogonal components.
Two samples were excluded based on the PCA analysis for (B). Filled box: positive samples, Open circle: negative samples.
doi:10.1371/journal.pone.0025563.g006




Mean (sd) 1.461.6 cm
Range 0.5–3.5 cm
Histologic type








Receptor and HER-2/neu status
ER+ PR+ HER-2/neu+ 6
ER+ PR2 HER-2/neu+ 4
ER+ PR2 HER-2/neu2 1
ER2 PR2 HER-2/neu+ 2
doi:10.1371/journal.pone.0025563.t001
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be an interesting point to focus on in a larger study.
Our approach did not yield a reliable discrimination model for
ER status (data not shown), whereas it did provide a reasonable
distinction for PR status. Recently, Giskeødega ˚rd et al. presented a
good prediction for the two prognostic markers based on HR-
MAS studies with surgically obtained tissue samples [12]. In their
case, most patients had a similar ER/PR status whereas the two
factors were hardly correlated in our patient groups. Therefore, it
is not surprising that there are differences between the results for
their and our patient groups. Another important prognostic
marker is axillary lymph node status. We could obtain a
reasonable classification only after the exclusion of two non-
metastatic samples based on a PCA analysis. At this point, it is not
clear what properties of these two samples made them closer to the
metastatic ones, which issue might be elucidated with a larger-
sample-size study. Still, the difficulty in lymph node status
prediction is not surprising in that a recent study also reported
an unsatisfactory result [12]. As noted in that study, earlier high-
accuracy results [15] could not be directly compared, due to the
lack of a blind test.
In conclusion, the HR-MAS MR metabolomics approach was
shown to be feasible with intact breast tissues obtained by core
needle biopsy. Specifically, our results show that this approach has
the potential to discriminate cancer and non-cancer and to classify
breast cancers according to their metabolite profiles. If validated in
a larger study, the approach may be used as a complement to the
current diagnostic and prognostic measures for the management of
women with breast cancers.
Materials and Methods
Ethics Statement
Institutional review board approval was obtained for this
prospective study from the Seoul National University Hospital
Institutional Review Board (H-1003-037-312), and all patients
provided written informed consent.
Patients
Between May 2010 and November 2010, 22 consecutive
women (mean age, 49 years; age range, 20–68 years) who had
been scheduled to undergo an ultrasound-guided percutaneous 14
gauge- core needle biopsy were examined. We had obtained the
31 breast tissue samples (13 cancer, 9 benign and 9 normal) from a
total of 22 women (13 patients with breast cancer and 9 patients
with benign tumors) (Table 2). The normal breast tissue samples
were obtained from sites adjacent to the periphery of the benign
tumors from patients with benign breast tumors by simply
changing the direction of the needle. Among the cancer patients,
eleven of them had infiltrating ductal carcinoma and the rest of
two had ductal carcinoma in situ. Four of the patients with
infiltrating ductal carcinoma also had metastasis on the lymph
nodes (Table 1). We did not apply any exclusion criteria and
analyzed all the samples of the patients enrolled in the study to
maximize the patient diversity.
For HR-MAS MR spectroscopy, tissue samples were placed in
cryogenic vials and were immersed in liquid nitrogen immediately
after dissection.
MR spectroscopy data acquisition
All one-dimensional HR-MAS MR spectra of the tissue samples
were measured with an NMR spectrometer (Agilent, VNMRS
500) operating at a proton NMR frequency of 500.13 MHz (11.7
T). Temperature was set to 19uC after calibration with methanol.
Each experiment took 1 hour and 5 minutes.
Frozen samples were thawed in NMR laboratory, weighed, and
placed into an HR-MAS nano-probeH (Agilent, Walnut Creek,
CA). The total volume of the sample cell is 40 ml, and an average
of 12.2 mg core-biopsy samples were put in the cell with the
remaining volume filled with D2O (0.01% TSP). The probe was
an inverse-detection type and equipped with single Z-gradient coil.
The spectra were taken with CPMG pulse sequence to impose a
T2 filter. The total T2 delay was set to 290 msec and the sample
was spun at 2 KHz. The spectra were acquired with total complex
points of 16 K, sweep width of 7961 Hz, and 1024 transients. The
90 degree pulse was calibrated with each sample on water
resonance. Water signal was saturated using weak power
continuous wave during the recycle delay.
Data processing
The time-domain spectra were apodized with exponential
function (1 Hz), and then Fourier-transformed, phased and
baseline-corrected manually. Spectra were referenced to the TSP
signal at 0.00 ppm which was also checked by alanine signals at
1.48 ppm in case the TSP signal is split due to protein binding. To
reduce the complexity of the NMR data for the subsequent
multivariate analysis, the spectra were binned by 0.005 ppm
interval and normalized by integration values over the region of
0.99,5.59 ppm. As the aliphatic lipid signals were vastly different
from sample to sample, only the regions that are not affected by
those signals were used (1.44,1.91 ppm and 2.15,5.59 ppm).
Within those regions, the water region (4.61,5.03) was excluded
in the normalization due to its irregular behavior. These binning
and normalization were done using an in-house built Perl
program. To compensate for possible peak shift mismatch due
to the relatively high resolution binning, the spectra were aligned
using correlation-optimized warping algorithm [35].
Multivariate and spectral analysis
Matlab (MathWorks, Natick, MA), SIMCA-P 11.0 (Umetrics,
Sweden), and Excel (Microsoft, Seattle, WA) programs were used
to process the numeric data for statistical analysis. Chenomx
(Spectral database; Edmonton, Alberta, Canada) was used for
Table 2. Clinical and histological data on 31 samples from 22




Mean (range) 49 (20–68)
Histologic Diagnosis
Cancer
Infiltrating Duct Carcinoma (IDC) 11






*Normal samples (n=9) were obtained from the patient with benign tumors.
doi:10.1371/journal.pone.0025563.t002
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square-discriminant analysis, and OPLS-DA were performed to
identify latent patterns and distinguish patient groups. Class
discrimination models were built until the cross-validated
predictability value does not meaningfully increase to avoid
over-fitting of the statistical model. The statistical model was
validated by prediction of the unknown samples using leave-one-
out analysis. An a priori cut-off value of 0.5 was used to evaluate
the prediction results [2]. Signals contributing to the class
differentiation were identified by S-plot and the corresponding
metabolites were identified using Chenomx (Spectral database;
Edmonton, Alberta, Canada) software and an in-house built
database.
Immunohistochemistry
After HR MAS analysis, each core needle biopsy specimen was
fixed in ice-cold acetone for histopathology. One 5 mm section
was cut from each frozen tissue, and stained with haematoxylin-
eosin (H&E) for microscopic examination by a pathologist.
Another section was stained immunohistochemically for estrogen
receptor (ER), progesterone receptor(PR), and HER-2/neu using
monoclonal mouse-anti-human ER (ab7825, abcam, USA), PR
(sc52358, santa cruz, USA) and HER-2/neu (sc71667, santa cruz,
USA) and Dako REAL EnVision Peroxidase/DAB+ in a Dako
Autostainer Plus.
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